Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 4/20 | 0.41 |
| ▸ | TK2 | O00142 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23009591 | 1.00 | RNASE1 (0.47) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL21216111 | 1.00 | RNASE1 (0.47) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL21216284 | 1.00 | RNASE1 (0.47) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL23211630 | 0.93 | RNASE1 (0.40) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL23225341 | 0.93 | RNASE1 (0.40) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL23211636 | 0.93 | RNASE1 (0.40) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL22977549 | 0.87 | RNASE1 (0.46) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL30932980 | 0.87 | RNASE1 (0.43) | RNASE1TK1TK2 | |
| SCHEMBL30932978 | 0.85 | RNASE1 (0.43) | RNASE1TK1TK2 | |
| SCHEMBL21216117 | 0.84 | RNASE1 (0.43) | RNASE1TK1TK2ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | SILICON VALLEY BANK | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | RNASE1 70/4885TK1 152/4885TK2 149/4885 |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | RNASE1 156/4885TK1 150/4885TK2 235/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | RNASE1 70/4885TK1 152/4885TK2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.